⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398511 | 1.00 | — | — | |
| SCHEMBL398333 | 1.00 | — | — | |
| SCHEMBL1650264 | 0.97 | CHRNB2 (0.54) | — | |
| SCHEMBL2670823 | 0.97 | CHRNB2 (0.54) | — | |
| SCHEMBL5770258 | 0.97 | CHRNB2 (0.54) | — | |
| SCHEMBL6371293 | 0.97 | CHRNB2 (0.54) | — | |
| SCHEMBL5831543 | 0.97 | CHRNB2 (0.54) | — | |
| SCHEMBL637612 | 0.97 | CHRNB2 (0.54) | — | |
| SCHEMBL1650265 | 0.89 | CHRNB2 (0.47) | — | |
| SCHEMBL6371186 | 0.89 | CHRNB2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 597 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144795-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | H. LUNDBECK A/S (DK) | 2026-05-28 | — | — | US | disclosed |
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12624028-B2 | 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4720076-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | H. Lundbeck A/S (DK) | 2026-04-08 | — | — | EP | disclosed |
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | ARVINAS OPERATIONS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12590106-B2 | Spiromacrocyclic orexin 2 receptor agonists | H. LUNDBECK A/S (DK) | 2026-03-31 | — | — | US | disclosed |
| EP-4709716-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | Bugworks Research, Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-1740591-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1664021-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005097800-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005021531-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-0413762-B1 | PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES | IGEN INT INC (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-0413762-A4 | PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES | — | 1992-01-15 | — | — | EP | disclosed |
| EP-0413762-A1 | PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES | IGEN, INCORPORATED (US) | 1991-02-27 | — | — | EP | disclosed |
| WO-1989010961-A1 | PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES | IGEN, INC. (US) | 1989-11-16 | — | — | WO | disclosed |